Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × Sulfonylurea Compounds × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 220 Carboplatin 159 Injections 116 Paclitaxel 110 Cisplatin 110 Bevacizumab 102 Gemcitabine 101 Pemetrexed 77 Docetaxel 74 Cyclophosphamide 54 Capecitabine 52 Fluorouracil 50 Oxaliplatin 47 Nivolumab 45 Fulvestrant 45 Cetuximab 45 130-nm albumin-bound paclitaxel 43 Dexamethasone 40 atezolizumab 39 Rituximab 38 Leucovorin 37 fludarabine 36 venetoclax 34 toripalimab 33 Lenalidomide 32 Drug Therapy 32 enzalutamide 31 durvalumab 30 trastuzumab deruxtecan 28 Prednisone 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-03-19

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡